Anti-diarrhoeal and ulcer-protective effects of violacein isolated from Chromobacterium violaceum in Wistar rats

Fundamental and Clinical Pharmacology

Volumn 23, Issue 4, 2009, Pages 483-490

  Antonisamy, Paulrayer ^a   Kannan, Ponnusamy ^a   Ignacimuthu, Savarimuthu ^a  

^a LOYOLA COLLEGE   (India)

Author keywords

Anti diarrhoeal; Anti enteropooling; Chromobacterium violaceum; Ulcer protective; Violacein

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIULCER AGENT; ATROPINE; CASTOR OIL; CHLORPROMAZINE; CIMETIDINE; LOPERAMIDE; MAGNESIUM SULFATE; UNCLASSIFIED DRUG; VIOLACEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM ISOLATE; CHROMOBACTERIUM VIOLACEUM; CONTROLLED STUDY; DEFECATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG STRUCTURE; FECES; FEMALE; INTESTINE TRANSIT TIME; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; STOMACH EMPTYING; STOMACH ULCER;

ANIMALS; ANTI-ULCER AGENTS; ANTIDIARRHEALS; CASTOR OIL; CHROMOBACTERIUM; DIARRHEA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL TRANSIT; INDIA; INDOLES; MAGNESIUM SULFATE; MALE; RATS; RATS, WISTAR; STOMACH ULCER;

EID: 68749090137     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00701.x     Document Type: Article

References (56)

1. Hirchhorn N. The treatment of acute diarrhoea in children: an historical and physiological perspective. Am. J. Clin. Nutr. (1980) 33 637 663.
2. Muriithi A.W. Control of diarrhoea disease programme. The Kenyan situation. Afr. Med. J. (1996) 281 189 195.
3. Field M., Rao M.C., Chang E.B. Intestinal electrolyte transport and diarrhoea disease. N. Engl. J. Med. (1989) 321 800 806.
4. Avery M.E., Synder J.D. Oral therapy for acute diarrhoea. Ant. J. Med. (1990) 323 891 894.
5. Anonymous. Diarrhoeal Disease Control Programme. Weekly Epidemic Record (1979) 16 121.
6. Synder J.D., Merson M.H. The magnitude of the global problem of acute diarrhoeal disease: a review of active surveillance data. Bull. WHO (1982) 60 605 613.
7. Lutterodt G.D. Inhibition of gastrointestinal release of acetyl choline by quercetin as possible mode of action of Psidium guajava leaf extracts in the treatment of acute diarrhoeal disease. J. Ethnopharmacol. (1989) 25 235 249.
8. Goodman L.S., Gilman A. Agents affecting gastrointestinal water flux and motility. Pharmacol. Basis Therap. (1992) 2 914 931.
9. Martinez I., Rorvik L.M., Brox V., et al. Genetic variability among isolates of Listeria monocytogenes from food products, clinical samples and processing environments, estimated by RAPD typing. Int. J. Food Microbiol. (2003) 84 285 297.
10. Chattopadhyay A., Kumar V., Bhat N., et al. Chromobacterium violaceum infection: a rare but frequently fatal disease. J. Pediatr. Surg. (2002) 37 108 110.
11. Duran N., Justo G.Z., Carmen V., et al. Violacein: properties and biological activities. Biotechnol. Appl. Biochem. (2007) 48 127 133.
12. Vasconcelos A.T.R., Almeida D.F., Hungria M., et al. The complete genome sequence of Chromobacterium violaceum reveals remarkable and exploitable bacterial adaptability. Proc. Natl Acad. Sci. USA (2003) 100 11660 11665.
13. Duran N., Menck C.F.M. Chromobacterium violaceum: a review of pharmacological and industrial perspective. Crit. Rev. Microbiol. (2001) 27 201 222.
14. Melo P.S., Maria S.S., Vidal B.C., et al. Violacein cytotoxicity and induction of apoptosis in V79 cells. In Vitro Cell Dev. Biol. Anim. (2000) 36 539 543.
15. Konzen M., De Marco D., Cordova C.A.S., et al. Antioxidant properties of violacein: possible relation on its biological function. Bioorg. Med. Chem. (2006) 14 8307 8313.
16. Leon L.L., Miranda C.C., De Souza A.O., et al. Antileishmanial activity of the violacein extracted from Chromobacterium violaceum. J. Antimicrob. Agents Chemother. (2001) 48 449 450.
17. Carvalho D.D., Costa F.T.M., Duran N., et al. Cytotoxic activity of violacein in human colon cancer cells. Toxicol. In Vitro. (2006) 20 1514 1521.
18. Kodach L.L., Bos C.L., Duran N., et al. Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. Carcinogenesis (2006) 27 506 516.
19. Ferreira C.V., Bos C.L., Versteeg H.H., et al. Molecular mechanism of violacein-mediated human leukemia cell death. Blood (2004) 104 1459 1464.
20. De Souza A.O., Aily D.C.G., Sato D.N., et al. Atividade da violaceina in vitro sobre o Mycobacterium turbeculosis H37RA. Rev. Inst. Adolfo. Lutz. (1999) 58 59 62.
21. Caldas L.R., Leitao A.A.C., Santos S.M. et al. Preliminary experiments on the photobiological properties of violacein, in : Tyrrell R.M. (Ed. Proceedings of the International Symposium on Current Topics in Radiology and Photobiology, Academia Brasileira de Ciencias, Rio de Janeiro, 1978, pp. 121 126.
22. Duran N., Campos V., Riveros R., Joyas A., et al. Bacterial chemistry: III. Preliminary studies on the trypanosomal activities of Chromobacterium violaceum products. An. Acad. Bras. Cienc. (1989) 61 31 36.
23. Duran N., Antonio R.V., Haun M., et al. Biosynthesis of a trypanocide by Chromobacterium violaceum. World J. Microbiol. Biotechnol. (1994) 10 686 690.
24. May G., Brummer B., Ott H. Treatment of prophylaxis of polio and herpes virus infections - comprises admin. of 3-(1,2-dihydro-5-(5-hydroxy-1H- indol-3-yl)-2-oxo-3H-pyrrole-3-ylidene)-1,3-dihydro-2H-indol-2-one. Ger Offen DE 3935066. 1991.
25. Duran N. Formulation of cyclodextrin/violacein based medicine-comprises enhancement of violacein solubility, with increase in versatility. Brazilian patent, Pi 9801307-A. 1998 [79451].
26. Andrighetti-Frohner C.R., Antonio R.V., Creczynski-Pasa T.B., et al. Cytotoxicity and potential antiviral evaluation of violacein produced by Chromobacterium violaceum. Mem. Inst. Oswaldo Cruz, Rio de Janeiro (2003) 98 843 848.
27. Bromberg N., Duran N. Violacein transformation by peroxidases and oxidases: implications on its biological properties. J. Mol. Catal B: Enzyme (2001) 11 463 467.
28. Cappuccino J.G., Sherman N. Microbiology: a laboratory manual, Pearson Education (Singapore Pvt. Ltd.), Singapore, 2004, pp. 137 185.
29. Hao C., Zhang H., Has R., et al. A novel community of acidophiles in an acid mine drainage sediment. World J. Microbiol. Biotechnol. (2007) 23 15 21.
30. Rettori D., Duran N. Production, extraction and purification of violacein: an antibiotic pigment produced by Chromobacterium violaceum. World J. Microbiol. Biotechnol. (1998) 14 665 668.
31. Nakamura Y., Sawada T., Morita Y., et al. Isolation of a psychrotrophic bacterium from the organic residue of a water tank keeping rainbow trout and antibacterial effect of violet pigment produced from the strain. Biochem. Eng. J. (2002) 12 79 86.
32. Riveros R., Haun M., Campos V., et al. Bacterial chemistry - IV. Complete characterization of violacein: an antibiotic and trypanocide pigment from Chromobacterium violaceum. Arquivos de Biologiae Tecnologia (Brazil) (1988) 31 475 487.
33. Parimata-Devi B., Boominathan R., Mandal S.C. Evaluation of antidiarrhoeal activity of Cleome viscosa L. extract in rats. Phytomedicine (2002) 9 739 742.
34. Shoba F.G., Thomas M. Study of antidiarrhoeal activity of four medicinal plants in castor oil induced diarrhoea. J. Ethnopharmacol. (2001) 76 73 76.
35. Gamaniel K.S., Akah P.A. Analysis of the gastrointestinal relaxing effect of the stem extract of Gongronema latifolium. Phytomedicine (1996) 2 293 296.
36. Doherty S.S. Inhibition of arachidonic acid release, mechanism by which glucocorticoids inhibit endotoxin-induced diarrhoea. Br. J. Pharmacol. (1981) 73 549 554.
37. Aniagu S.O., Bindaa L.G., Nwinyia F.C., et al. Anti-diarrhoeal and ulcer-protective effects of the aqueous root extract of Guiera senegalensis in rodents. J. Ethnopharmacol. (2005) 97 549 554.
38. Adami E., Marzi-ubertti E., Turba C. Pharmacological research of gefarnate, a new synthetic isoprenoid with an anti ulcer action. Arch. Int. Pharm. Ther. (1964) 147 113 145.
39. Melo P.S. Pigmentos obtidos de Chromobacterium violaceum Serratia marcescens, Propriedade tripanocida da prodigiosina estudos toxicoloagicos, Master's Thesis. Biology Institute, Campinas State University, Campinas, SP, Brazil, 1996.
40. Duran N., Erazo S., Campos V. Bacterial chemistry-II: antimicrobial photo product from pigment f Chroobacterium violaceum. Anais Acad. Brasil. Ciencias (1983) 55 231 234.
41. Laatsch H., Thomson T.H., Cox P.J. Spectroscopic properties of violacein and related compounds: crystal structure of tetramethylviolacein. J. Chem. Soc. Perkin Trans. II. (1984) 2 1331 1339.
42. Dias L.C. Jr., Neto J.D.D.M., Rettori D., et al. Semiempirical INDO/S stud on the absorptin spectrum of violacein. J. Mol. Struct. (2002) 580 85 90.
43. Ammon H.V., Thomas P.J., Phillips S. Effect of oleic and recinoleic acid on net jejunal water and electrolyte movement. J. Clin. Invest. (1974) 53 374 379.
44. Gaginella T.S., Stewart J.J., Olson W.A., et al. Action of recinoleic acid and structurally related fatty acid on the gastrointestinal tract II. Effect on water a electrolyte absorption in-vitro. J. Pharmacol. Exp. Therap. (1975) 195 355 361.
45. Beubler E., Juan H. Effect of ricinoleic acid and other laxatives on net water flux and prostaglandin E release by the rat colon. J. Pharm. Pharmacol. (1979) 31 681 685.
46. Luderer J.R., Dermers L.N., Hayn A.T., Advances in Prostaglandin and Thromboxane Research, Raven Press, New York, 1980, pp. 1633 1638.
47. Awouters F., Nimegeers C.J.E., Lenaerts F.M., Janssen P.A.J. Delay of castor oil diarrhoea in rats; a new way to evaluate inhibitors of prostaglandin biosynthesis. J. Pharm. Pharmacol. (1978) 30 41 45.
48. Galvez J., Zarzuelo A., Crespo M.E., et al. Antidiarrhoeic activity of Euphorbia hirta extract and isolation of an active flavanoid constituent. Planta Med. (1993) 59 333 336.
49. Theoderau V., Fioramont J., Hachet T., et al. Absorptive and motor components of anti-diarrhoeal action of loperamide: an in vivo study in pigs. Gut (1991) 32 1355 1359.
50. Tripathi K.D. Essentials of Medical Pharmacology, Jay Pee Brothers. Medical Publishers, New Delhi, 1994.
51. Lewis D.A., Hanson P.J. Antiulcer drugs of plant origin. Prog. Med. Chem. (1991) 28 201 229.
52. Akah P.A., Gamaniel K.S., Wambebe C.N., et al. Studies on gastrointestinal properties of Ficus exasperata. Fitoterapia (1997) 68 17 20.
53. Glavin G.B., Szabo S. Experimental gastric mucosal injury: Laboratory models reveal mechanisms of pathogenesis and new therapeutic strategies. Fed. Am. Soc. Exp. Biol. J. (1992) 6 825 831.
54. Cho C.H., Ogle C.W. The pharmacological differences and similarities between stress- and ethanol-induced gastric mucosal damage. Life Sci. (1992) 51 1833 1842.
55. Bertaccini G., Scapignato C. Histamine H2 antagonists modify gastric emptying in rats. Br. J. Pharmacol. (1981) 77 434 448.
56. Seiji I., Emiko O.A., Toshiaki M. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociception and nocistatin. Neurosci. Res. (2001) 41 299 332.